← Back to Clinical Trials
Recruiting NCT05853419

NCT05853419 Change History and Adopt a Robotic SolutioN for anGioplasty procedurE

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05853419
Status Recruiting
Phase
Sponsor Robocath
Condition Coronary Disease
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2023-06-20
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 120 Years
Study Type OBSERVATIONAL
Interventions
Robotic-assisted PCI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2023-06-20 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.

Eligibility Criteria

Inclusion Criteria: * 1\. Age ≥ 18 years; * 2.Subjects with coronary artery disease with clinical indication for PCI; * 3.Subject deemed appropriate for robotic-assisted PCI; and * 4.The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. Exclusion Criteria: * 1.Failure/inability/unwillingness to provide informed consent, unless the ethic committee has waived informed consent; or * 2.The Investigator determines that the subject or the coronary anatomy is not suitable for robotic-assisted PCI. * 3.STEMI * 4.Cardiogenic shock * 5.Subjects will not be included if they are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.

Contact & Investigator

Central Contact

Hamouda Abassi, PhD

✉ hamouda.abassi@robocath.com

📞 +33 2 32 10 67 42

Principal Investigator

Stefan Verheye, Prof.MD

PRINCIPAL INVESTIGATOR

Het Ziekenhuisnetwerk Antwerpen vzw

Frequently Asked Questions

Who can join the NCT05853419 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Coronary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05853419 currently recruiting?

Yes, NCT05853419 is actively recruiting participants. Contact the research team at hamouda.abassi@robocath.com for enrollment information.

Where is the NCT05853419 trial being conducted?

This trial is being conducted at Antwerp, Belgium, Brest, France, Rouen, France, Saint-Denis, France and 4 additional locations.

Who is sponsoring the NCT05853419 clinical trial?

NCT05853419 is sponsored by Robocath. The principal investigator is Stefan Verheye, Prof.MD at Het Ziekenhuisnetwerk Antwerpen vzw. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology